Skyhawk Therapeutics is pleased to be presenting at the upcoming EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium highlighting preclinical data on SKY-1214, the company’s investigational, oral FANCL/FANCI targeting RNA splicing modulator being developed for difficult to treat multiple myeloma and non-Hodgkin’s lymphoma. Read the full release here: https://lnkd.in/eHhSV9sh #MultipleMyeloma #EORTC #NCI #AACR #RareDisease #SkyhawkTx #DrugDevelopment #SmallMoleculeRNA #RNA #BloodCancer
Skyhawk Therapeutics
生物技术研究
Waltham，Massachusetts 9,600 位关注者
We Use Small Molecules To Modify RNA Splicing
关于我们
Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease. Our first drug candidates are targeted toward cancers and neurological conditions. The company is based in Waltham, Massachusetts. For more information, please visit: www.skyhawktx.com.
- 网站
-
https://www.skyhawktx.com
Skyhawk Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Waltham，Massachusetts
- 类型
- 私人持股
- 创立
- 2016
地点
-
主要
获取路线
180 3rd Ave., Sixth Floor
US，Massachusetts，Waltham，02451
Skyhawk Therapeutics员工
动态
-
Skyhawk Therapeutics is pleased to present additional topline data from Parts A and B of its Phase 1 clinical trial of SKY-0515 at the European Huntington’s Disease Network and Enroll-HD 2024 meeting in Strasbourg, France. Skyhawk is currently enrolling Huntington’s patients in Part C of its Phase 1 clinical trial and is on track to report topline data from the trial in Q2 2025. Learn More: https://lnkd.in/eJ2Jpf4V #HuntingtonsDisease #EHDN #RareDisease #SkyhawkTx #DrugDevelopment #SmallMoleculeRNA #RNA
-
-
Skyhawk Therapeutics Announces Positive Topline Results from Parts A and B of its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction The Skyhawk team is delighted with the speed at which this study was conducted and thrilled to report such compelling results for SKY-0515. These topline data represent a crucial step forward for SKY-0515 and demonstrate the immense potential of the Skyhawk platform to target indications for which there are no approved disease modifying therapies. Learn More: https://lnkd.in/eYBJAnUH #HuntingtonsDisease #DrugDevelopment #Skyhawk #SmallMoleculeRNA?
-
-
Skyhawk Therapeutics is pleased to announce the recent promotion of Clint Musil from Chief Financial Officer to Chief Executive Officer and the appointment of Bill Haney as Executive Chairman of the Board of Directors, effective February 2024. “Clint is an exceptional leader with considerable public biopharma company experience. With Skyhawk’s first program for Huntington’s disease progressing in the clinic and our second program on track to enter the clinic, Clint’s talent, energy and focus are ideally suited to drive Skyhawk as we work towards continued growth.” – Bill Haney, Executive Chairman of the Board of Directors. Learn More: https://lnkd.in/eY25eNqp
-
-
The Skyhawk Therapeutics team is excited to be on the ground in New York City for the Jefferies Healthcare Conference! #RNA #DrugDevelopment #SmallMoleculeRNA #SkyhawkTx #Jefferies24
-
-
The Skyhawk Therapeutics team is excited to connect with other biotech pioneers this week at the BIO International Conference in San Diego from June 3-6! #RNA #DrugDevelopment #SmallMoleculeRNA #SkyhawkTx #BIO24
-
-
SKY-0515 is a small molecule RNA splicing modifier developed through our novel SKYSTAR??platform.?Having successfully advanced through single asending dose,?SKY-0515 is advancing into the Multiple Ascending Dose portion of its phase 1 study for Huntington's Disease https://lnkd.in/g8JKgDh7